Intestinal Diseases  >>  oxaliplatin  >>  Phase 1
Welcome,         Profile    Billing    Logout  

18 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
oxaliplatin / Generic mfg.
NCT01286818: A Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B)

Checkmark ASCO-GI 2013
Jan 2013 - Jan 2013: ASCO-GI 2013
Completed
1b
6
Japan
Ramucirumab (IMC-1121B), IMC-1121B, Ramucirumab, LY3009806, Irinotecan, levofolinate, 5-Fluorouracil (5-FU)
Eli Lilly and Company
Colorectal Carcinoma
02/12
03/12
NCT00660153: Study of Tivozanib (AV-951) Plus FOLFOX6 in Subjects With Advanced Colorectal Cancer and Other Gastrointestinal Cancers

Checkmark P1 data-ASCO
Jun 2012 - Jun 2012: P1 data-ASCO
Completed
1b
30
Europe
Tivozanib (AV-951) plus FOLFOX6
AVEO Pharmaceuticals, Inc.
Colorectal Cancer, Gastrointestinal Cancer
06/12
06/12
NCT00499850: Phase I FOLFOX Combination

Completed
1
18
RoW
ZD6474 (vandetanib), ZACTIMA™, 5-Fluorouracil, 5-FU, Leucovorin, Oxaliplatin
Genzyme, a Sanofi Company
Advanced Colorectal Carcinoma
06/06
04/08
NCT00353262: A Study of Xeloda (Capecitabine) in Combination With Oxaliplatin in Patients With Metastatic Colorectal Cancer.

Completed
1
36
Canada
Avastin, Oxaliplatin, capecitabine [Xeloda]
Hoffmann-La Roche
Colorectal Cancer
09/06
04/08
NCT00403052: A Study of 1018 Immunostimulatory Sequence (ISS) Administered With Irinotecan and Cetuximab to Treat Patients With Previously Treated Metastatic Colorectal Cancer

Terminated
1
14
US
1018 ISS immunostimulatory oligonucleotide
Dynavax Technologies Corporation
Colorectal Neoplasms
12/07
12/07
NCT00599924: Study Of Sunitinib Plus FOLFOX In Patients With Solid Tumors

Checkmark P1 data (Solid tumor)
May 2012 - May 2012: P1 data (Solid tumor)
Completed
1
53
US
sunitinib + FOLFOX, Sunitinib malate, SUTENT, mFOLFOX6
Pfizer
Colorectal Neoplasms, Neoplasms
11/08
11/08
NCT00631410: Study Of Sunitinib In Combination With Folfox In Patients With Colorectal Cancer

Checkmark P1 data
Mar 2012 - Mar 2012: P1 data
Completed
1
12
Japan
sunitinib + mFOLFOX6
Pfizer
Colorectal Neoplasms
07/09
03/10
NCT01271166: Glivec® Plus m-FOLFOX Avastin® in Advanced Colorectal Cancer

Terminated
1
10
RoW
Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab
Novartis Pharmaceuticals
Advanced Colorectal Cancer
08/09
 
NCT00387387: Study On Pazopanib When Given With FOLFOX6 (Fluorouracil, Oxaliplatin, Leucovorin) Or CapeOx (Capecitabine, Oxaliplatin)

Completed
1
50
Europe, RoW
Pazopanib, FOLFOX 6, CapeOx
GlaxoSmithKline
Neoplasms, Colorectal
08/09
08/09
NCT00478634: A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer

Completed
1
19
US
RAD001, Cetuximab, Irinotecan
Novartis Pharmaceuticals
Colorectal Cancer, Colorectal Carcinoma, Colorectal Tumors, Neoplasms, Colorectal
09/09
09/09
NCT00101894: Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer

Checkmark P2 data - ESMO 2012
Sep 2012 - Sep 2012: P2 data - ESMO 2012
Completed
1
119
US
FOLFOX-4, AMG 706, Panitumumab (Part 1a only), FOLFIRI
Amgen
Rectal Cancer, Colon Cancer
04/10
12/11
NCT00532909: Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer

Completed
1
13
US
Vandetanib, Capecitabine, Oxaliplatin, Bevacizumab
Branimir Sikic, AstraZeneca
Anal, Colon, and Rectal Cancers, Colorectal Neoplasms, Colon/Rectal Cancer
05/10
05/10
NCT00920868: XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib

Completed
1
22
US
dasatinib, Sprycel, bevacizumab, Avastin, Oxaliplatin, Eloxatin, Capecitabine, Xeloda
Herbert Hurwitz, MD, Bristol-Myers Squibb
Solid Tumor, Metastatic Colorectal Cancer
05/10
08/14
NCT00779311: A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer

Terminated
1
8
US
sorafenib, Nexavar, bevacizumab, Avastin, mFOLFOX6 regimen
Accelerated Community Oncology Research Network, Bayer
Metastatic Colorectal Cancer
03/11
03/11
NCT00934882: Study to Determine Safety, Pharmacokinetics, Pharmacodynamics of BAY73-4506 in Combination With mFOLFOX6 or FOLFIRI

Checkmark Combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer
Mar 2013 - Mar 2013: Combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer
Checkmark P1 data (CRC)
May 2012 - May 2012: P1 data (CRC)
Completed
1
45
Europe
Regorafenib (BAY73-4506)
Bayer
Colorectal Neoplasms
04/12
04/12
NCT00940758: Phase I and Pharmacokinetic Study of Biweekly PEP02 in mCRC Refractory to 1st-line Oxaliplatin Base Therapy

Completed
1
18
RoW
PEP02
PharmaEngine
Metastatic Colorectal Cancer
05/12
06/14
NCT00879385: KRAS Wild-type Metastatic Colorectal Cancer Trial

Checkmark +decitabine
Mar 2013 - Mar 2013: +decitabine
Completed
1
21
US
Dacogen™ (decitabine), Vectibix® (panitumumab)
University of Utah, Amgen, Eisai Inc.
Colorectal Cancer
01/13
01/13
NCT02041481: MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer

Checkmark In combination with FOLFOX for colorectal cancer at ASCO GI 2016
Jan 2016 - Jan 2016: In combination with FOLFOX for colorectal cancer at ASCO GI 2016
Completed
1
26
US
MEK inhibitor MEK162, ARRY-162, ARRY-438162, Binimetinib, MEK inhibitor ARRY-438162, MEK162, leucovorin calcium, CF, CFR, LV, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, pharmacological study, pharmacological studies, Laboratory Biomarker Analysis
City of Hope Medical Center, National Cancer Institute (NCI), Array BioPharma
Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
01/18
01/18

Download Options